Brokers Offer Predictions for Traws Pharma Q3 Earnings

Traws Pharma, Inc. (NASDAQ:TRAW) – Equities researchers at HC Wainwright decreased their Q3 2026 EPS estimates for shares of Traws Pharma in a research report issued to clients and investors on Tuesday, August 18th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.08). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Traws Pharma’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.02 EPS.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.18.

Other equities research analysts have also recently issued reports about the stock. LADENBURG THALM/SH SH cut shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Citigroup lowered Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. Finally, Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Traws Pharma currently has an average rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Stock Performance

Traws Pharma stock opened at $0.54 on Thursday. Traws Pharma has a one year low of $0.43 and a one year high of $3.27. The business has a fifty day moving average of $0.68 and a two-hundred day moving average of $1.32. The company has a market cap of $8.30 million, a P/E ratio of -0.31 and a beta of 1.57.

Hedge Funds Weigh In On Traws Pharma

A number of large investors have recently modified their holdings of TRAW. State Street Corp purchased a new position in Traws Pharma in the fourth quarter valued at approximately $29,000. Two Sigma Investments LP increased its position in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after acquiring an additional 5,955 shares in the last quarter. XTX Topco Ltd increased its position in shares of Traws Pharma by 294.2% in the fourth quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after acquiring an additional 31,502 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Traws Pharma in the 4th quarter valued at $56,000. Finally, Geode Capital Management LLC raised its stake in shares of Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares during the period. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.